Answers are grounded in this paper and cite their sources.
Modeling neurological diseases using human embryonic or patient-derived induced pluripotent stem cells (iPSCs) improves the understanding of molecular and cellular changes underlying these diseases and can lead to new, potentially personalized therapies. Changes in expression of axon guidance cues and altered cytoskeletal maintenance have been implicated in neurodegenerative and neuropsychiatric disorders. To date, most of the iPSC patient-derived cellular dysfunction and phenotypic studies have been performed in vitro. To study the intrinsic axonal impairments and neuronal connectivity deficits in human disease iPSC-derived neurons we propose to graft these cells into the physiological three-dimensional multi-structural environment of the central nervous system of rodent models to obtain relevant in vivo data. Such human iPSC in vivo chimeric models can allow for neuronal maturation, capture neuropathological phenotypes of axonal and connectivity impairments, and serve as target engagement and drug validation studies using human cells, thus highly relevant for advancement of the drug development process in the late pre-clinical stages. • Xeno-transplanted iPSC patient-cell generated neurons survive, mature and innervate their destined brain target zones. • Neurons differentiated from patient ES/iPSCs can model human functional changes when xenografted into rodent models. • Neuronal grafts can capture disease specific functional changes and connectivity impairments. • The human iPSC xeno-transplants provide for late drug validation in physiological contexts and pharmacokinetic studies.
No takes yet. Share an insight, caveat, or question.
Korecka et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: